Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Xianlu Q. Lennon"'
Autor:
Robert N Booher, Harold Hatch, Brian M Dolinski, Thi Nguyen, Lauren Harmonay, Ali-Samer Al-Assaad, Mark Ayers, Michael Nebozhyn, Andrey Loboda, Heather A Hirsch, Theresa Zhang, Bin Shi, Carrie E Merkel, Minilik H Angagaw, Yaolin Wang, Brian J Long, Xianlu Q Lennon, Nathan Miselis, Vincenzo Pucci, James W Monahan, Junghoon Lee, Anna Georgieva Kondic, Eun Kyung Im, David Mauro, Rebecca Blanchard, Gary Gilliland, Stephen E Fawell, Leigh Zawel, Alwin G Schuller, Peter Strack
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e108371 (2014)
Dinaciclib is a potent CDK1, 2, 5 and 9 inhibitor being developed for the treatment of cancer. Additional understanding of antitumor mechanisms and identification of predictive biomarkers are important for its clinical development. Here we demonstrat
Externí odkaz:
https://doaj.org/article/b410584fec734e0e84be6d52d5590862
Autor:
Mark Ayers, Brian Long, Rebecca L. Blanchard, Andrey Loboda, Eun Kyung Im, Gary Gilliland, Nathan R. Miselis, Minilik Angagaw, Junghoon Lee, Vincenzo Pucci, Anna Georgieva Kondic, Alwin Schuller, Yaolin Wang, Carrie E. Merkel, Brian Dolinski, Peter Strack, Lauren Harmonay, Theresa Zhang, Michael Nebozhyn, Xianlu Q. Lennon, Ali-Samer Al-Assaad, James W. Monahan, Bin Shi, Harold Hatch, Leigh Zawel, David J. Mauro, Heather Hirsch, Robert Booher, Stephen Fawell, Thi D.T. Nguyen
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e108371 (2014)
PLoS ONE
PLoS ONE
Dinaciclib is a potent CDK1, 2, 5 and 9 inhibitor being developed for the treatment of cancer. Additional understanding of antitumor mechanisms and identification of predictive biomarkers are important for its clinical development. Here we demonstrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3ce916dba21fb31cc577869fd4e7111
http://europepmc.org/articles/PMC4188521?pdf=render
http://europepmc.org/articles/PMC4188521?pdf=render